It is well documented that glucocorticoid excess causes bone loss, but the mechanisms of these effects remain poorly defined. To understand further the mechanisms of glucocorticoid-induced osteoporosis, we investigated the effects of glucocorticoids on bone formation and bone resorption by examining the proliferation, functional activities, and cytokine secretion of cultured human bone marrow stromal cells (hBMSC). Treatment with dexamethasone for 24 h at the concentration of 10 8 M significantly suppressed [ 3 H]thymidine incorporation and further inhibition was observed with longer treatment (8 days) or higher concentration (10 7 M). Alkaline phosphatase activity of hBMSC was markedly stimulated with addition of dexamethasone (10 8 M), to 191 22% (after 4 days) and 317 46% (after 7 days) of control. Dexamethasone (10 8 M) treatment for 48 h decreased the incorporation of [ 3 H]proline into collagenasedigestible protein (CDP; 43·7 7·9% of control) and non-collagen protein (65·2 8·4% of control), with a greater effect on CDP. Northern blot analysis indicated that 1(I)-collagen mRNA level was decreased by dexamethasone to 27·6 9·0% of the control value after 1 day of exposure, and to 55·2 6·2% after 7 days. Dexamethasone markedly suppressed basal production of interleukin (IL)-6 and IL-11 and that stimulated by parathyroid hormone (PTH), IL-1 , or tumour necrosis factor-in a dose-dependent manner. These results suggest that the glucocorticoid-induced bone loss is derived at least in part via inhibition of bone formation, which includes the suppression of osteoblast proliferation and collagen synthesis. As both basal and PTH-stimulated production of IL-6 and IL-11 are decreased by dexamethasone, the increased bone resorption observed in glucocorticoidinduced osteopenia does not appear to be mediated by IL-6 or IL-11.
Introduction
Osteoporosis is one of the most serious side effects of long-term high-dose glucocorticoid therapy, but the mechanisms of bone loss remain poorly defined. Previous studies have suggested that glucocorticoid excess causes bone loss by two mechanisms: suppression of bone formation and stimulation of bone resorption (Canalis 1996 , Reid 1997 . The data regarding the effects of glucocorticoids on osteoblast activities in vitro, however, are conflicting. They appear to depend upon whether physiological or pharmacological concentrations of the hormone are used, on the time and duration of exposure to the drug, and on the particular system investigated (Bellows et al. 1987) . Experiments using organ cultures of fetal or neonatal bone have shown that exposure to glucocorticoids increases collagen synthesis and alkaline phosphatase activityparameters of osteoblast differentiation -after 24 h of culture, but decreases these parameters after 96 h (Dietrich et al. 1979 , Canalis 1983 , Kream et al. 1997 . In addition, both stimulation and inhibition of cell proliferation by glucocorticoids have been reported in these organ cultures (Tenenbaum & Heersche 1985 , McCulloch & Tenenbaum 1986 , Kream et al. 1997 . In isolated osteoblast-like cell populations, glucocorticoids decrease cell proliferation but increase alkaline phosphatase activity (Chen et al. 1977 , Wong et al. 1990 , Cheng et al. 1994 . The effects of glucocorticoids on collagen expression in osteoblast-like cells, however, remain controversial. Both stimulation and inhibition have been reported depending on the osteoblast systems and culture conditions (Wong 1979 , Kasugai et al. 1991 , Shalhoub et al. 1992 , Fernandez & Minguell 1997 .
Glucocorticoids have been shown to stimulate osteoclast-like cell formation directly (Kaji et al. 1997) and to increase bone resorption in neonatal mouse calvaria (Conaway et al. 1996) . In addition, glucocorticoid administration causes secondary hyperparathyroidism as a result of impaired gut calcium absorption and hypercalciuria (Canalis 1996 , Reid 1997 . As parathyroid hormone (PTH) is an important stimulator of osteoclast activities mediated via osteoblasts (Suda et al. 1995) , it is possible that glucocorticoids may also induce bone resorption indirectly via PTH. Consistent with this possibility, PTH responses in osteoblast-like cells are increased by glucocorticoids (Chen & Feldman 1978) and dexamethasone enhances PTH-stimulated osteoclast-like cell formation and bone resorption (Kaji et al. 1997) . Recently, the osteoclast-activating effects of PTH are shown to be mediated by interleukin (IL)-6 and IL-11 secreted by osteoblasts (Manolagas et al. 1994) . However, the effects of glucocorticoid on IL-6 and IL-11 production in human osteoblastic cells have not been thoroughly explored.
Although these accumulated data indicate that glucocorticoids have profound effects on osteoblast activities that, in turn, alter osteoclast activities, it is still unclear which of these glucocorticoid-induced changes contribute to osteoporosis in human bone. It has been well documented that bone marrow stromal cells include actively proliferating osteoprogenitor cells, and these cells can be induced to differentiate into cells exhibiting osteoblast phenotype by dexamethasone (Haynesworth et al. 1992 , Vilamitjana-Amedee et al. 1993 ,Cheng et al. 1994 . To investigate the mechanisms of bone loss incurred by glucocorticoid administration in humans, we studied the effects of dexamethasone on the proliferation, differentiated activities, and production of bone-resorbing cytokines in normal human bone marrow stromal cells.
Materials and Methods
Human bone marrow stromal cell (hBMSC) culture hBMSC were isolated from ribs obtained at the time of open thoracotomy in patients without metabolic bone disease, as previously described (Cheng et al. 1994) . This study was approved by the Institutional Ethics Committee of the Asan Medical Center, and all patients gave informed consent. Briefly, the ribs were excised aseptically, cleaned of soft tissues, and opened longitudinally. The bone marrow cells were flushed out using several washes of serumfree -minimum essential medium ( -MEM; Sigma, St Louis, MO, USA), and purified via Ficoll/Hypaque (specific gravity 1·077; Nycomed, Oslo, Norway) gradient centrifugation. The cells were seeded into a 75 cm 2 plastic culture flask at a density of 4 10 5 cells/cm 2 and cultured in -MEM containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA). When the bone marrow stromal cells had grown to 80% confluence, they were then subcultured and the first-or second-passage cells were used for experiments. Previously, we have shown that, when cultured to confluence in the presence of serum, the hBMSC possess many of the phenotypic characteristics of differentiated osteoblasts, such as production of osteocalcin and deposition of mineralized matrix (Cheng et al. 1994 , 1996 , Kim et al. 1997 (Benz et al. 1977) .
Alkaline phosphatase activity
hBMSC were seeded into 12-well plates at a density of 4 10 4 cells/well and cultured for 2 days in -MEM containing 5% FBS. Then the media were exchanged for fresh medium containing 0·1% bovine serum albumin (BSA) with or without addition of dexamethasone (10 8 M). After 72 h of culture, the medium was removed and the alkaline phosphatase activity of the cell layer was measured by the p-nitrophenyl phosphate hydrolysis method (Puzas & Brand 1985) . The data were normalized with cellular protein contents to represent the alkaline phosphatase activity as nmol/µg protein per min.
Measurement of collagen synthesis
Collagen synthesis was measured by the incorporation of [ 3 H]proline (Amersham, Arlington Heights, IL, USA) into collagenase (type VII, Sigma) digestible protein. Cells in 12-well plates were grown to confluence (7 days), followed by treatment with medium containing 100 µg/ml ascorbic acid, 100 µg/ml -aminopropionitrile fumarate and 10 8 M dexamethasone or vehicle for 48 h. [ 3 H]Proline (5 µCi/ml) was added for the last 24 h. The medium was removed and the cell layers were harvested by scraping into water containing l mg/ml BSA and the following protease inhibitors: 2·5 mM N-ethylmaleimide, 0·2 mM phenylmethylsulfonyl fluoride, and 2·5 mM Na 2 EDTA. The cell layers were sonicated for 10 s and TCA was added to a final concentration of 15%. Samples were stored at 4 C overnight, followed by centrifugation at 3000 g for 20 min at 4 C. The precipitates were washed three times with 5% TCA, dissolved in 50 µl 1 M NaOH and adjusted to 1 ml by adding 0·1 M HEPES, pH 7·3, containing 3·5 mM CaCl 2 and protease inhibitors described above. Samples were divided into equal aliquots and incubated with or without bacterial collagenase, the incorporation of [ 3 H]proline into collagenase digestible protein (CDP) and non-collagen protein (NCP) was determined, and % collagen synthesis was calculated as the ratio of CDP/total protein (Peterkofsky & Diegelmann 1971) .
Northern blot analysis
Human bone marrow stromal cells in p-150 culture dishes were treated with vehicle (control) or dexamethasone (10 8 M) for the indicated period of time. PolyA + mRNA-enriched RNA preparation was isolated using the Mini RiboSep mRNA isolation kit (Collaborative Biomedical Products, Bedford, MA, USA). mRNAs were separated on formaldehyde-containing agarose gels and transferred to nylon membranes. The membranes were prehybridized with a solution containing 40% formamide, 5 SSC (0·75 M NaCl in 75 mM sodium citrate, pH 7·0), 10 mM Tris, pH 7·4, 1·25 Denhardt solution and 125 µg/ml salmon testes DNA at 42 C overnight, then hybridization was performed in a fresh solution containing the same ingredients as the prehybridization solution with additional 10% dextran sulfate and [ 32 P]-cDNA probe for human type I collagen (kindly provided by Dr William Parks, Washington University, St Louis, MO, USA) and for human -actin (kindly provided by Dr Bratin Saha, Emory University, Atlanta, GA, USA) overnight at 42 C.
[ 32 P]cDNAs were prepared using the Megaprime Labeling kit (Amersham, Arlington Heights, IL, USA) and 5 - [ -32 P]dCTP (3000 Ci/mmol, aqueous solution). After two washes with 2 SSC and 0·5% SDS for 15 min each at room temperature and a single wash with 02 SSC and 0·5% SDS at 52 C, the membranes were exposed to hyperfilms (Amersham) at 70 C.
Assessment of IL-6 and IL-11 production by hBMSC
The cells (3 10 4 cells/well) were subcultured in 48-well plates containing -MEM and 5% charcoal-stripped serum for 2 days. Then the cells were treated with dexamethasone (10 9 -10 7 M) for 24 h, followed by the addition of stimulating agents, PTH (10 8 M; Sigma), IL-1 (500 U/ ml; Sigma), or tumour necrosis factor (TNF)-(10 11 M; Sigma), and continued culture for an additional 72 h. The amounts of IL-6 and IL-11 secreted by hBMSC in the conditioned media were measured by ELISA using commercial kits (IL-6 ELISA kit, Genzyme, Cambridge, MA, USA; IL-11 kit, R&D systems, Minneapolis, MN, USA).
Statistics
All experiments were repeated at least three times using hBMSC preparations obtained from different patients, and 
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representative data are shown in the figures. All data are expressed as means ... The significance of the differences were assessed by Mann-Whitney U-test between two groups, and by analysis of variance (ANOVA) with post hoc analysis by Duncan's multiple range test among three or more groups. Dose-response relationships were examined by Spearman's rank correlation analysis.
Results

Effect of dexamethasone on [ 3 H]thymidine incorporation
Treatment with dexamethasone for 24 h at the concentration of 10 8 M suppressed [ 3 H]thymidine incorporation to 82 4% of the control (P<0·05) (Fig. 1) . Further inhibition was observed with longer duration (8 days) of treatment (P<0·01) or greater concentration (10 7 M, P<0·001), suggesting that dexamethasone affects proliferation of hBMSC in a time-and dose-dependent manner.
Effect of dexamethasone on alkaline phosphatase activity
Alkaline phosphatase activity of hBMSC was very high, and was markedly stimulated with addition of dexamethasone (10 8 M) to 191 22% of the control after 4 days of culture (P<0·01) and to 317 46% after 7 days (P<0·001) (Fig. 2) .
Effect of dexamethasone on collagen synthesis
As shown in Table 1 , dexamethasone treatment for 48 h decreased the synthesis of total protein and of CDP and NCP in hBMSC. Total protein synthesis was decreased to 60 7% of the control value (P<0·05), whereas the incorporation of [ 3 H]proline into CDP was reduced to 44 8% of the control value (P<0·01). The incorporation of [ 3 H]proline into NCP was also decreased (P<0·05), but not to the same extent as that into CDP. As a result, the percentage of collagen synthesis/total protein synthesis in dexamethasone-treated cells was significantly lower than that in the control culture (P<0·05).
Consistent with the decreased collagen protein synthesis, Northern blot analysis indicated that the steadystate mRNA level of 1(I)-collagen was decreased by dexamethasone (10 8 M) after 1 day of treatment (P<0·01) (Fig. 3) . After 7 days, the type I collagen mRNA level remained depressed (P<0·01), although to a lesser extent. Long-term treatment (2-4 weeks) with dexamethasone further decreased collagen mRNA expression and reached 32 8% of the control (P<0·01) by 4 weeks.
The dose-response curve also indicated that dexamethasone decreased type I collagen mRNA level in a concentration of 10 9 M (P<0·01), the maximal effect being observed with a concentration of 10 8 M (Fig. 4) .
Effects of dexamethasone on IL-6 and IL-11 production
Dexamethasone suppressed the basal IL-6 secretion by hBMSC in a dose-dependent manner (Fig. 5, ) . The inhibition was apparent at 10 9 M dexamethasone and increased with greater concentrations. In contrast, PTH enhanced IL-6 production to 150% of control (Fig. 5A ). This induction, however, was abolished by the presence of dexamethasone, effective in concentrations as low as 
10
9 M. IL-1 and TNF-also stimulated the expression of IL-6 in hBMSC to two-to threefold the control level (Fig. 5B) . The IL-6 production stimulated by IL-1 or TNF-was lower in the presence of high concentrations of dexamethasone than that in the absence of dexamethasone; however, the dexamethasone suppression curves for IL-1 -or TNF--stimulated IL-6 production were parallel with the curves for basal production, suggesting that dexamethasone did not inhibit the stimulation by IL-1 or TNF-.
Dexamethasone also suppressed the basal IL-11 production by hBMSC in a dose-dependent manner (Fig. 6) . The inhibition occurred at 10 8 M or greater concentrations. PTH stimulated the secretion of IL-11 to more than Figure 3 Effects of dexamethasone (Dex, Dexa) on the steady state mRNA levels of type I collagen in hBMSC. Cells were treated with vehicle (control, C) or dexamethasone at 10 8 M for 1-28 days. The relative type I collagen mRNA concentration on the autoradiograms was analyzed by densitometer and normalized with the -actin mRNA level. The ratio of type I collagen/ -actin for the control culture after 1 day of treatment was defined as 100% (n=8, *P<0·01 compared with control).
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twofold the control level, and this stimulation was inhibited by dexamethasone dose dependently from the concentration of 10 9 M (Fig. 6A) . Likewise, IL-1 and TNF-increased IL-11 secretion by hBMSC and this stimulation was eliminated by dexamethasone at 10 8 M or greater concentrations (Fig. 6B) .
Discussion
Our studies have demonstrated that dexamethasone inhibited the proliferation and matrix protein synthesis of osteoblastic cells. In addition, dexamethasone inhibited the production of IL-6 and IL-11 -cytokines that are known to mediate the bone-resorptive actions of PTH. These results suggest that the mechanisms of decreased bone formation by glucocorticoids are derived in part via the inhibition of osteoblast proliferation and matrix protein synthesis. Moreover, they also suggest that the increased bone resorption by glucocorticoids is not mediated by IL-6, IL-11 or PTH.
Although long-term use of pharmacological doses of glucocorticoids results in osteoporosis in vivo, it has been reported that glucocorticoids induce differentiation of osteoprogenitor cells into osteoblasts (Haynesworth et al. 1992 , Vilamitjana-Amedee et al. 1993 , Cheng et al. 1994 . These seemingly paradoxical effects of glucocorticoid can be explained by the inhibition of proliferation of osteoprogenitor cells. Although glucocorticoids stimulate the differentiation of osteoprogenitor cells to osteoblasts, the inhibition of their proliferation may diminish the supply of these osteoprogenitor cells, and decrease the numbers of osteoblasts and bone formation. It has also been suggested that physiological levels of glucocorticoids are necessary for osteoblast differentiation, and high levels of glucocorticoid drastically reduce proliferation of the osteoblastic precursors (Scutt et al. 1996) . Our findings that dexamethasone decreased [
3 H]thymidine incorporation and markedly increased alkaline phosphatase activity are consistent with such a concept.
Conflicting results have been reported on the effects of glucocorticoids on the expression of type I collagen. Glucocorticoid can stimulate, inhibit, or have a biphasic effect on collagen mRNA expression, depending on the osteoblast systems and culture conditions (Dietrich et al. 1979 , Kasugai et al. 1991 , Shalhoub et al. 1992 , Yao et al. 1994 . In rat BMSC, dexamethasone decreased the level of type I collagen mRNA during the first 6 or 7 days of treatment, followed by a rebound to near control on day 9 and, finally, an increase of four-to fivefold 14-28 days after treatment (Kasugai et al. 1991 , Leboy et al. 1991 , Yao et al. 1994 . Our results showed that the expression of type I collagen mRNA in hBMSC was decreased 1 day after treatment, and slightly rebounded in the next 7 days, although the level remained inhibited by dexamethasone over a 4-week period. Consistent with the decreased amount of collagen mRNA, the synthesis of collagen protein was suppressed 48 h after dexamethasone exposure. The reason for such differences in results compared with previous studies is not clear, but the differences in species, stages of differentiation of the cells, or doses of corticosteroids could have affected the findings.
As prolonged treatment (2-4 weeks) with dexamethasone reverts the inhibition of collagen mRNA to approximately 30% of the control levels, these data suggest that overall collagen deposition to the bone matrix may be decreased over a prolonged period of time. During bone remodeling, it is essential for preosteoblastic cells to migrate and adhere to the bone surface to begin synthesis and deposition of bone matrix for the repair of the cavities left behind by osteoclasts. With the decrease in collagen deposition as a result of prolonged glucocorticoid administration, the availability of the collagen for osteoblast adhesion will be reduced, consistent with the decreased numbers of osteoblasts on the bone surface observed in glucocorticoid-induced osteoporotic bone (Canalis 1996 , Gronowicz & McCarthy 1995 . We have previously Figure 4 Effects of dexamethasone on the steady-state mRNA levels of type I collagen in hBMSC as a function of dose. hBMSC were treated with vehicle (control, 0) or dexamethasone at indicated concentrations for 7 days. The relative type I collagen mRNA concentration on the autoradiogram was analyzed by densitometer and normalized with the -actin mRNA level. The ratio of type I collagen/ -actin for the control culture was defined as 100% (n=8, *P<0·01 compared with control).
Figure 5
Effects of dexamethasone on IL-6 production of hBMSC. Cells were stimulated with PTH (10 8 M), IL-1 (500 U/ml), or TNF-(10 11 M) in the presence of various concentrations of dexamethasone for 72 h and the amounts of IL-6 secreted into the media were measured by ELISA (n=8; *P<0·01, **P<0·001 compared with no dexamethasone).
Figure 6
Effects of dexamethasone on IL-11 production of hBMSC. Cells were stimulated with PTH (10 8 M), IL-1 (500 U/ml), or TNF-(10 11 M) in the presence of various concentrations of dexamethasone for 72 h (n=8, *P<0·001 compared with no dexamethasone).
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demonstrated that dexamethasone decreased the mRNA levels of osteopontin and bone sialoprotein, and osteocalcin concentration in hBMSC (Cheng et al. 1996) . Consistent with these observations, the synthesis of non-CDPs was decreased in cells treated with dexamethasone. The decrease in osteopontin and bone sialoprotein will further reduce the adhesion sites available for osteoblasts (Grzesik & Robey 1994) . Previous animal experiments showed that enhanced resorption during glucocorticoid administration could be prevented by parathyroidectomy (Kukreja et al. 1976) , suggesting that secondary hyperparathyroidism may play a major role in steroid-induced bone resorption in vivo. In humans, however, the role of secondary hyperparathyroidism in glucocorticoid-induced bone loss has not been confirmed. Although some investigators have found increased serum concentrations of PTH, these are frequently reported to be in the normal range (Hahn et al. 1979 , Hattersley et al. 1994 . Some authors have suggested that glucocorticoids enhance the sensitivity of osteoblasts to PTH (Chen & Feldman 1978 , Wong 1979 , Catherwood 1985 . However, our study showed that dexamethasone markedly suppressed the production of cytokines such as IL-6 and IL-11, which mediate PTH effects. These results are in agreement with some previous reports (Haynesworth et al. 1996 , Swolin-Eide & Ohlsson 1998 . Taking these findings together, it can be suggested that increase of bone resorption by glucocorticoid is not mediated by IL-6 or IL-11. In addition, these results do not support the contention that glucocorticoid-induced bone loss is mediated by the increased secretion of PTH, which is known to stimulate bone resorption mainly via increased secretion of IL-6/IL-11. However, there is still a possibility that PTH acts via some other mediators. Recently, it has been shown that PTH stimulates receptor activator of the NF-B ligand (RANKL), which induces osteoclast differentiation (Yasuda et al. 1998 ) and also stimulates osteoclast activity (Lacey et al. 1998) . Further study is required to understand the mechanism(s) of increased bone resorption in glucocorticoid-induced osteoporosis.
